Avaí Bio

Avaí Bio partners with leading-edge biotech firms, universities, scientists, and clinicians to uncover innovative solutions for diverse healthcare challenges, and then drive the development of advanced therapies that improve patient outcomes and quality of life.  Our mission is to transform healthcare through cutting-edge cellular technology and protective live-cell encapsulation, reshaping how patients see their available treatment options. 

Avaí Bio currently has two development programs in its cellular therapies pipeline, a diabetes development program and an α-Klotho protein development program.  Avaí has secured Joint Venture and Licensing Agreements to develop both programs.